Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that bind directly to
thrombin and block its interaction with its substrates. Four parenteral DTIs have been …

This chapter about the recognition, treatment, and prevention of heparin-induced
thrombocytopenia (HIT) is part of the Seventh ACCP Conference on Antithrombotic and …

This chapter about the recognition, treatment, and prevention of heparin-induced
thrombocytopenia (HIT) is part of the Antithrombotic and Thrombolytic Therapy: American …

Heparin-induced thrombocytopenia (HIT) is a potentially devastating immune mediated
adverse drug reaction caused by the emergence of antibodies that activate platelets in the …

A 63-year-old man with coronary artery disease who has recently undergone bypass
surgery presents with dyspnea. Laboratory testing reveals a platelet count of 86,000 per …

Unfractionated heparin given during cardiopulmonary bypass is remarkably immunogenic,
as 25% to 50% of postcardiac surgery patients develop heparin-dependent antibodies …

more often in cardiovascular surgical patients than in orthopedic surgical patients, in
postsurgical patients than in medical patients, in those treated with bovine heparin than …

Bivalirudin is a direct thrombin inhibitor (DTI) frequently used for anticoagulation in the
setting of invasive cardiology, particularly percutaneous coronary intervention (PCI) …

Heparin was discovered 90 years ago, 1 and within 2 decades it was being widely used as
an anticoagulant. 2 The numerous advantages of heparin lend to its broad use including its …

Heparin-induced thrombocytopenia is a prothrombotic adverse drug effect induced by
platelet-activating antibodies against multimolecular complexes of platelet factor 4 and …